loading

Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스

pulisher
Jun 06, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Lis - GuruFocus

Jun 06, 2025
pulisher
Jun 05, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 05, 2025
pulisher
Jun 05, 2025

Intellia Therapeutics Expands CRISPR Team: 33,600 RSUs Granted to New Leadership - Stock Titan

Jun 05, 2025
pulisher
Jun 04, 2025

How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% - sharewise

Jun 04, 2025
pulisher
Jun 04, 2025

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - TradingView

Jun 04, 2025
pulisher
Jun 03, 2025

(NTLA) Investment Report - news.stocktradersdaily.com

Jun 03, 2025
pulisher
Jun 03, 2025

Intellia Therapeutics (NTLA) Price Target Adjusted by Canaccord Genuity | NTLA Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Up - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Intellia Therapeutics (NTLA) Sees Price Target Cut Amid Study Updates | NTLA Stock News - GuruFocus

Jun 03, 2025
pulisher
May 31, 2025

ARK Investment Acquires 226K Shares of Intellia Therapeutics (NT - GuruFocus

May 31, 2025
pulisher
May 30, 2025

Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration - Benzinga

May 30, 2025
pulisher
May 30, 2025

ARK Investment Acquires 226K Shares of Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock By Investing.com - Investing.com Nigeria

May 30, 2025
pulisher
May 30, 2025

Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock - Investing.com Australia

May 30, 2025
pulisher
May 30, 2025

Intellia slides after safety concern for Regeneron-partnered gene editing therapy - MSN

May 30, 2025
pulisher
May 30, 2025

StockWatch: Intellia Stumbles on News of Patient’s Severe Liver Toxicity - Genetic Engineering and Biotechnology News

May 30, 2025
pulisher
May 30, 2025

NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study - Yahoo Finance

May 30, 2025
pulisher
May 30, 2025

Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip - MSN

May 30, 2025
pulisher
May 30, 2025

Intellia shares tumble on safety signal in gene-editing trial - The Pharma Letter

May 30, 2025
pulisher
May 30, 2025

Intellia stock dips following safety event in Phase III gene therapy trial - Clinical Trials Arena

May 30, 2025
pulisher
May 30, 2025

Intellia Therapeutics (NTLA) Receives Continued 'Buy' Rating fro - GuruFocus

May 30, 2025
pulisher
May 29, 2025

Intellia: Shares Sink on Safety Concern in Phase 3 Trial; Lowering Fair Value to $60 From $75 - Morningstar

May 29, 2025
pulisher
May 29, 2025

ARK Investment Acquires Significant Stake in Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

No-Moat Intellia's Gene-Editing Pipeline Looks Promising for Long-Term, Risk-Tolerant Investors - Morningstar

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics (NTLA) Faces Challenges Amid Safety Concer - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics (NTLA) Faces Revised Price Target Amid Stu - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Intellia adverse event could resurface questions, says JPMorgan - TipRanks

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics (NTLA) Faces Setback with Late-Stage Trial Incident - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Intellia: Heart Disease Safety Setback Triggers SelloffCaution Advised (NASDAQ:NTLA) - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Intellia Shares Drop 19% After Safety Signal Emerges in Phase 3 Trial - MSN

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics Shares Drop 25 Percent After Liver Stress Reported in Gene-Editing Trial - geneonline.com

May 29, 2025
pulisher
May 29, 2025

Intellia tumbles on liver safety signal for CRISPR therapy - FirstWord Pharma

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics Faces Safety and Efficacy Challenges with Nex-Z: Analyst Issues Sell Rating - TipRanks

May 29, 2025
pulisher
May 29, 2025

Intellia filing spurs safety concerns over CRISPR drug - BioPharma Dive

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course - Benzinga

May 29, 2025
pulisher
May 29, 2025

Intellia commercial position in question after safety event. says Goldman - TipRanks

May 29, 2025
pulisher
May 29, 2025

Intellia Plunges in Latest Example of Gene Therapy Troubles - Bloomberg

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics (NTLA) Faces Challenges Amid Safety Concerns | NTLA Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Analysts Brush Off Intellia’s Adverse Event but Gene Therapy Safety Concerns Continue - BioSpace

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics (NTLA) Faces Revised Price Target Amid Study Concerns | NTLA Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Intellia stock holds $45 target despite AE concerns By Investing.com - Investing.com Nigeria

May 29, 2025
pulisher
May 29, 2025

Intellia's stock sinks on gene therapy patient's raised enzyme levels, but analysts keep faith - Fierce Biotech

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics (NTLA) Stock Drops After Trial Update | NT - GuruFocus

May 29, 2025
pulisher
May 29, 2025

H.C. Wainwright maintains $30 target on Intellia stock post-safety update - Investing.com

May 29, 2025
pulisher
May 29, 2025

Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews - Benzinga

May 29, 2025
pulisher
May 29, 2025

Cantor maintains Intellia stock at $65 target despite trial concern By Investing.com - Investing.com India

May 29, 2025
pulisher
May 29, 2025

Intellia stock tumbles on safety concerns By Investing.com - Investing.com Canada

May 29, 2025
pulisher
May 29, 2025

Intellia stock tumbles on safety concerns - Investing.com

May 29, 2025
pulisher
May 29, 2025

Intellia stock down on safety concern for gene editing drug - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Wedbush Cuts Price Target on Intellia Therapeutics to $7 From $10, Keeps Neutral Rating - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

NTLA: Intellia Therapeutics Advances Key Clinical Trials | NTLA Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

BofA cuts Intellia stock target to $39, maintains Buy rating By Investing.com - Investing.com India

May 29, 2025
pulisher
May 29, 2025

Intellia stock holds after JMP reiterates market perform - Investing.com Australia

May 29, 2025
pulisher
May 29, 2025

Intellia stock holds after JMP reiterates market perform By Investing.com - Investing.com India

May 29, 2025
pulisher
May 29, 2025

Intellia Therapeutics: Buy Rating Affirmed Despite Safety Concerns in MAGNITUDE Study - TipRanks

May 29, 2025
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
자본화:     |  볼륨(24시간):